Since 10-31-05
Give em' an inch and they'll take a mile - More TRICARE drugs eyed for a $22 copay
Since 10-31-05
From: Waspscpo@aol.com
Sent: Wednesday, October 26, 2005 6:43 AM
To: undisclosed-recipients:
Subject: Give em' an inch and they'll take a mile
The Providence Journal (RI)-10/24/05
More TRICARE drugs eyed for a $22 copay
The trickle of drugs moving to TRICARE's third tier, at a copay of $22,
may become a flood. On Sept. 28, the Defense Department's Beneficiary Advisory
Panel was asked to consider a proposal by the Defense Department's Pharmacy and
Therapeutic Committee to move another 14 drugs to the high-priced level.
On the list were ACE inhibitors known as Univasc, Aceon, Accupril and Altace,
which are taken for high blood pressure. Also included were the calcium channel
blockers Verelan, Verelan PM, Covera HS, Cardizem LA, Norvasc, DynaCirc,
DynaCirc CR, Cardene and Cardene SR. In addition, alpha-blocker Flomax, taken
for benign prostate enlargement, was being considered for third tier placement.
The third tier is used for extremely costly drugs that have less expensive
generic counterparts equally effective for treating the same condition.
Principal DoD deputy for health affairs, Dr. William Winkenwerder, will
ultimately make the final decision on what drugs will be on the list soon.
Another version......
ARMED
FORCES NEWS
MORE TRICARE DRUGS EYED FOR $22 COPAY
Oct. 14, 2005
The trickle of drugs moving to Tricare's third tier -- at a copay of $22 -- may
become a flood. On Sept. 28, the Defense Department's Beneficiary Advisory Panel
was asked to consider a proposal by the DoD Pharmacy and Therapeutic Committee
to move another 14 drugs to the high-priced level.
On the list were ACE Inhibitors Univasc, Aceon, Accupril, and Altace (for high blood pressure).
Also included were Calcium Channel Blockers Verelan, Verelan PM, Covera HS, Cardizem LA, Norvasc, DynaCirc, DynaCirc CR, Cardene, and Cardene SR (a different kind of blood pressure drug). In addition, Alpha-blocker Flomax, for benign prostate enlargement, was being considered.
The third tier is used for extremely costly drugs that have less expensive counterparts which are equally effective for treating the same condition.
Principal DoD deputy for health affairs, Dr. William Winkenwerder, will make the final decision.